Clinical Trial Update: Trilostane for Androgen-Independent Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing trilostane in androgen-independent prostate cancer has completed enrollment and results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Adenocarcinoma
• Prostate Cancer

Drugs mentioned

• Trilostane (trilostane)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Status: COMPLETED